AB Science Secures U.S. Patent for Masitinib in mCRPC Until 2042

Event summary

  • AB Science's U.S. patent for masitinib in treating metastatic castrate-resistant prostate cancer (mCRPC) extends protection until May 2042.
  • The patent complements existing European IP coverage and aligns with positive clinical data from study AB12003.
  • Masitinib is positioned as a combination therapy with docetaxel for mCRPC patients with low metastatic involvement.
  • Study AB12003 showed a 21% reduction in progression risk for masitinib plus docetaxel in patients with baseline ALP ≤250 IU/L.

The big picture

The U.S. patent grant strengthens AB Science's intellectual property position for masitinib, a drug targeting an unmet need in mCRPC. With limited therapeutic advancements in this space over the past two decades, masitinib's combination with docetaxel could address a significant gap in treating patients with low metastatic involvement. The patent extends AB Science's market exclusivity until 2042, providing a long-term competitive advantage in a disease area with high mortality rates and limited treatment options.

What we're watching

Regulatory Dynamics
Whether the U.S. patent grant will accelerate masitinib's regulatory approval process in other major markets.
Clinical Validation
The pace at which additional clinical data will support masitinib's efficacy in broader mCRPC patient populations.
Market Positioning
How AB Science will leverage this IP protection to differentiate masitinib in a competitive mCRPC treatment landscape.